文献速递妇科

基因组不稳定评分与新诊断非BRCA1/2卵巢癌患者无进展生存期和总生存期的关联

Association between genomic instability score and progression-free/overall survival in patients with newly diagnosed non-BRCA1/2 ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2024-12-07

本研究探讨基因组不稳定评分(GIS)与新诊断非BRCA1/2卵巢癌患者无进展生存期(PFS)和总生存期(OS)的关联。以GIS≥42为同源重组缺陷(HRD) cutoff,<42为同源重组 proficient(HRP)。结果显示GIS作为连续变量与更长的PFS和OS相关;HRD患者中位PFS为35.4个月,HRP为14.9个月(p<0.001);HRP患者中接受PARPi者中位PFS短于未接受者(12.7个月 vs 15.2个月)。

要点

  • GIS作为连续变量与新诊断非BRCA1/2卵巢癌更长的PFS和OS相关。
  • HRD(GIS≥42)患者中位PFS 35.4个月,显著长于HRP(GIS<42)的14.9个月(p<0.001)。
  • HRP患者中接受PARPi者中位PFS 12.7个月,短于未接受者的15.2个月。

核心结论

  • 在新诊断晚期非BRCA1/2卵巢癌中,GIS作为连续变量与更长的PFS和OS相关。
  • 在HRP卵巢癌患者中,PARPi治疗可能与更短的PFS相关,值得进一步评估。

研究设计与样本

  • 研究纳入新诊断非BRCA1/2卵巢癌患者,以GIS≥42为HRD cutoff,<42为HRP。
  • 收集维持治疗类型和持续时间等变量,构建多变量模型,以基线后6个月为界标分析,并应用于时间依赖变量。

主要发现

  • GIS作为连续变量与改善的PFS和OS相关。
  • HRD卵巢癌患者中位PFS为35.4个月(25.4-NE),HRP患者为14.9个月(13.1-16.2),p<0.001。
  • HRP患者中位OS为36.2个月(32.4-NE),HRD患者未达到,p=0.002。
  • HRP卵巢癌患者中,接受PARPi者中位PFS为12.7个月,未接受者为15.2个月。

关键数值与推荐

  • HRD定义为GIS≥42,HRP定义为GIS<42。
  • HRD患者中位PFS 35.4个月(25.4-NE)vs HRP患者14.9个月(13.1-16.2),p<0.001。
  • HRP患者中位OS 36.2个月(32.4-NE)vs HRD患者未达到,p=0.002。
  • HRP患者接受PARPi者中位PFS 12.7个月 vs 未接受者15.2个月。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 在HRP卵巢癌患者中PARPi治疗可能与更短PFS相关,值得进一步评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We sought to describe the association between genomic instability score (GIS) and progression-free survival (PFS) and overall survival (OS) in patients with newly diagnosed, non-BRCA1/2 ovarian cancer. METHODS: Homologous recombinant deficiency (HRD) status was based on a cutoff of ≥42 GIS; patients <42 were categorized with homologous recombination proficiency (HRP). We collected type and duration of maintenance therapy, among other variables, and built a multivariate model with landmark analysis at 6 months from baseline and applied it for time-dependent variables. RESULTS: Increasing GIS as a continuous variable was associated with improved PFS and OS in our cohort. Overall, median PFS was significantly longer in patients with HRD ovarian cancer (35.4 months, 25.4-NE) than in those with HRP disease (14.9 months, 13.1-16.2; p < 0.001). Median OS was 36.2 months (32.4-NE) for HRP and not reached for HRD (p = 0.002). Notably, in patients with HRP ovarian cancer, we observed a shorter median PFS in those who received a poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi) than in those who did not (12.7 months for HRP with PARPi vs 15.2 months for HRP without PARPi). CONCLUSIONS: Our results demonstrate that in newly diagnosed advanced non-BRCA1/2 ovarian cancer, GIS as a continuous variable is associated with longer PFS and OS. In patients with HRP ovarian cancer, PARPi treatment may be associated with shorter PFS, which warrants further evaluation.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Graves S, Sullivan MW, Adkoli A, et al. Association between genomic instability score and progression-free/overall survival in patients with newly diagnosed non-BRCA1/2 ovarian cancer. Gynecol Oncol. 2024. PMID: 39647188. doi:10.1016/j.ygyno.2024.11.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。